Videos

Alicia Morgans, MD, MPH, covers what sets darolutamide apart from other androgen receptor inhibitors.

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

Alicia Morgans, MD, MPH, discusses the ARANOTE trial.

An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept over ESAs, with an intriguing trend toward improved overall survival that warrants further investigation.

An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early and late ESA initiation, emphasizing that treatment timing remains an individualized decision.

An expert discusses how radiopharmaceuticals such as radium-223 offer a valuable different mechanism of action in treating advanced prostate cancer, requiring careful patient selection, safety monitoring including complete blood count (CBC) tracking, and practical management of adverse effects such as fatigue and nausea while following radiation safety protocols.

Emiltatug ledadotin demonstrated promising antitumor activity and a manageable safety profile in a phase 1 dose-escalation trial.

Shahzad Raza, MD, discusses the phase 2 RedirecTT-1 study which investigated the combination of talquetamab and teclistamab for treating patients with relapsed/refractory multiple myeloma complicated by extramedullary disease.

Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with metastatic anal cancer, while avoiding checkpoint inhibitors in solid organ transplant recipients and maintaining that different checkpoint inhibitors are not necessarily interchangeable without specific trial data.

Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in first-line metastatic anal cancer, leading to FDA approval despite nonsignificant overall survival results due to 45% crossover in the interim analysis.

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

Shahzad Raza, MD, explains the rationale behind the REDIRECTT-1 study.

Theresa Medina, MD, discusses the clinical potential of lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma.

A study strongly supports stereotactic radiation for up to 20 brain metastases, proving superior to even advanced whole-brain techniques and widely accessible.

The PROGRxN-BCa study, led by Jethro C.C. Kwong, showcases a major advancement in predicting disease progression in non–muscle-invasive bladder cancer through artificial intelligence (AI).

An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by demonstrating the potential superiority of antibody-drug conjugates (ADCs) combined with immunotherapy over standard chemotherapy regimens.

An expert discusses how recent clinical advancements and biomarker-driven strategies are reshaping first-line treatment decisions in metastatic triple-negative breast cancer (mTNBC), emphasizing the critical need for early, optimized therapy to improve outcomes in this aggressive disease.

Ayal Aizer, MD, MHS, discusses the findings of a phase 3 study investigating the use of stereotactic radiation vs whole-brain radiation in patients with 5 to 20 brain metastases.

Nicole A. Cipriani, MD, offers guidance for community oncologists regarding the role of BRAF p.V600E testing in patients with papillary thyroid carcinoma.

Breelyn Wilky, MD, explains when patients with gastrointestinal stromal tumor should be referred for clinical trials.

Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

Peter M. Voorhees, MD, shares key insights from the 2025 American Society of Clinical Oncology Annual Meeting, specifically in the multiple myeloma space.

Ponatinib improved MRD negativity and safety in Ph+ ALL patients in the PHALLcon study, supporting its role as a potent TKI despite long-term data pending.

A new risk model uses objective clinical data to predict cure or relapse in Hodgkin lymphoma, with future plans to guide treatment and survivorship care.

Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

A panelist notes that while new treatments like luspatercept and imetelstat offer hope beyond traditional erythropoiesis-stimulating agents—which fail in many patients and provide limited response duration—variability in patient response, influenced by factors such as mutation burden, underscores the need for personalized therapies and continued development of agents that can modify disease progression and improve survival in low-risk myelodysplastic syndrome.

A panelist highlights that after initial hemoglobin decline despite dose escalation, further increasing luspatercept dosing led to transfusion independence and hemoglobin improvement, underscoring the critical role of regular monitoring and timely dose adjustments to optimize anemia management in low-risk myelodysplastic syndrome.

An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic castration-resistant prostate cancer (mCRPC) without prior androgen receptor pathway inhibitor exposure, while other combinations such as radium-223 plus olaparib showed mixed results with concerning toxicity profiles.